Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 901 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Once Weekly Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 81
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more

Conditions: Hepatitis C
Interventions: TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV); Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more

Conditions: Obesity
Interventions: Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and placebo 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg, Semaglutide 2.4 mg and placebo 1.0 mg; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 25
States / cities: Birmingham, Alabama • Anaheim, California • Chula Vista, California + 22 more

Conditions: Cardiovascular Risk, Obesity
Interventions: Zenagamtide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 45 Years and older
Enrollment: 8,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 155
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 134 more

Conditions: Pancreatic Cancer
Interventions: MORAb-009, Placebo, Gemcitabine; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 26
States / cities: La Jolla, California • San Diego, California • Vallejo, California + 22 more

Conditions: Cocaine Dependence
Interventions: Modafinil, Cognitive Behavioral Therapy; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 25 Years to 50 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Rheumatoid Arthritis
Interventions: Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 47
States / cities: Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more

Conditions: Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
Interventions: bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy; Drug · Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bladder Cancer
Interventions: HS-410, Placebo, BCG; Biological
Lead sponsor: Heat Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 19
States / cities: Los Angeles, California • Sherman Oaks, California • Torrance, California + 16 more

Conditions: Hepatitis C, Chronic
Interventions: Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo; Drug
Lead sponsor: Tibotec BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 31
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more

Conditions: Cat Allergy, Cat Hypersensitivity
Interventions: AMG 157, Cat Immunotherapy, Cat Immunotherapy Placebo, AMG 157 Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more

Conditions: Major Depressive Disorder, Alcohol Use Disorder
Interventions: Ketamine + Naltrexone, Ketamine + Placebo, Placebo (psychoactive placebo midazolam) + Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Placebo, ATYR1940; Biological
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Rochester, New York • Columbus, Ohio

Conditions: Aging, Balance Deficits
Interventions: Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham; Device
Lead sponsor: Weinberg Medical Physics LLC; Industry
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: MabThera/Rituxan, Methotrexate, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 67
States / cities: Birmingham, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 54 more

Conditions: Obesity
Interventions: Ribupatide, Placebo; Drug
Lead sponsor: Kailera; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 35
States / cities: Mesa, Arizona • Sun City West, Arizona • Irvine, California + 31 more

Conditions: Diabetes Mellitus, Overweight, Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Escondido, California • Lomita, California + 12 more

Conditions: Obesity, Overweight
Interventions: NNC0174-0833, Semaglutide, Placebo (NNC0174-0833); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cocaine Dependence
Interventions: levodopa/carbidopa 400/100 BID; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Osteoarthritis, Overweight or Obesity
Interventions: Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 39
States / cities: Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 34 more

Conditions: Sarcopenia, Anabolic Resistance
Interventions: Resistance training, Resveratrol 500 mg oral once daily., Placebo; Behavioral · Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 60 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Semen Quality
Interventions: Leflutrozole, Dose 1, Leflutrozole, Dose 2, Leflutrozole, Dose 3, Placebo; Drug
Lead sponsor: ReproNovo Aps; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: North Hollywood, California • Pomona, California • Garden City, New York + 1 more

Conditions: Prediabetes, Type 2 Diabetes (T2DM)
Interventions: Vitamin D (Cholecalciferol ), Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 30 Years to 74 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leiomyosarcoma
Interventions: Unesbulin, Dacarbazine, Placebo; Drug · Other
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 18 more

Search by objective public record fields.

HEALEY ALS Platform Trial - Master Protocol

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Modafinil, Sleep Architecture and Cocaine Relapse

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Strength Training and Resveratrol

A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function

Vitamin D and Type 2 Diabetes - Treat-To-Target

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)